Literature DB >> 27559111

Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation.

Tatsuo Kakiuchi1,2, Taishi Takahara1,2, Yumiko Kasugai1, Kotaro Arita3, Noriaki Yoshida4,5, Kennosuke Karube6, Miyuki Suguro1, Keitaro Matsuo1, Hayao Nakanishi7, Tohru Kiyono8, Shigeo Nakamura2, Hirotaka Osada9,10, Yoshitaka Sekido9,10, Masao Seto4, Shinobu Tsuzuki1,11.   

Abstract

Mesotheliomas are frequently characterized by disruption of Hippo pathway due to deletion and/or mutation in genes, such as neurofibromin 2 ( NF2 ). Hippo disruption attenuates yes-associated protein (YAP) phosphorylation allowing YAP to translocate to the nucleus and regulate gene expression. The role of disrupted Hippo pathway in maintenance of established mesotheliomas has been extensively investigated using cell lines; however, its involvement in development of human mesothelioma has not been explored much. Here, we employed immortalized human mesothelial cells to disrupt Hippo pathway. YAP phosphorylation was reduced on NF2 knockdown and the cells exhibited altered growth in vitro , developing tumors when transplanted into nude mice. Similar results were obtained from enforced expression of wild-type or constitutively active (S127A) YAP, indicating the crucial role of activated YAP in the transformation of mesothelial cells. Gene expression analysis comparing control- and YAP-transduced immortalized human mesothelial cells revealed phospholipase-C beta 4 ( PLCB4 ) to be among the genes highly upregulated by YAP. PLCB4 was upregulated by YAP in immortalized human mesothelial cells and downregulated on YAP knockdown in Hippo-disrupted mesothelioma cell lines. PLCB4 knockdown attenuated the growth of YAP-transduced immortalized mesothelial cells and YAP-active, but not YAP-nonactive, mesothelioma cell lines. Our model system thus provides a versatile tool to investigate the mechanisms underlying mesothelioma development. We suggest that PLCB4 may be an attractive drug target for the treatment of mesothelioma.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2016        PMID: 27559111     DOI: 10.1093/carcin/bgw084

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

1.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.

Authors:  Akihiro Matsushita; Tatsuhiro Sato; Satomi Mukai; Teruaki Fujishita; Emi Mishiro-Sato; Maho Okuda; Masahiro Aoki; Yoshinori Hasegawa; Yoshitaka Sekido
Journal:  Oncogene       Date:  2018-11-06       Impact factor: 9.867

Review 2.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

Review 3.  The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Authors:  Xiao-Lan Liu; Rui Zuo; Wen-Bin Ou
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

4.  PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.

Authors:  Chien-Feng Li; Ting-Ting Liu; I-Chieh Chuang; Yen-Yang Chen; Fu-Min Fang; Ti-Chun Chan; Wan-Shan Li; Hsuan-Ying Huang
Journal:  Oncotarget       Date:  2017-03-21

Review 5.  Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Cancers (Basel)       Date:  2018-03-22       Impact factor: 6.639

6.  Establishment and characterization of CRISPR/Cas9-mediated NF2-/- human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.

Authors:  Md Wahiduzzaman; Sivasundaram Karnan; Akinobu Ota; Ichiro Hanamura; Hideki Murakami; Akihito Inoko; Md Lutfur Rahman; Toshinori Hyodo; Hiroyuki Konishi; Shinobu Tsuzuki; Yoshitaka Hosokawa
Journal:  Cancer Sci       Date:  2018-12-14       Impact factor: 6.716

7.  Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma.

Authors:  Sivasundaram Karnan; Akinobu Ota; Hideki Murakami; Md Lutfur Rahman; Muhammad Nazmul Hasan; Md Wahiduzzaman; Ichiro Hanamura; Lam Quang Vu; Akihito Inoko; Toshinori Hyodo; Hiroyuki Konishi; Shinobu Tsuzuki; Yoshitaka Hosokawa
Journal:  Cell Death Discov       Date:  2020-11-18

8.  An Overview of Asbestos and Malignant Pleural Mesothelioma: An Iranian Perspective

Authors:  Habib Emami; Alireza Ilbeigi; Kian Khodadad
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

Review 9.  NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.

Authors:  Tatsuhiro Sato; Yoshitaka Sekido
Journal:  Int J Mol Sci       Date:  2018-03-26       Impact factor: 5.923

10.  PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia.

Authors:  Shiwen Wu; Wei Zhang; Dongqin Shen; Jianle Lu; Li Zhao
Journal:  Oncol Lett       Date:  2019-09-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.